## **Provider Order Form**

## **KISUNLA (DONANEMAB-AZBT)**



| Patient Demogra   | aphics 🔲 Insurance  |   | <b>OST EFFICIENTLY PF</b> supporting DX ☐ Baseline CSF, Lumbar, Blood test)                    |                                 |  |           |
|---|---|---|--|---------------------------------|--|-----------|
| <b>PATIENT</b>  |   |   |  |                                 |  |           |
| Full Name:  |   |   | DOB:   |                                 |  |           |
| Mobile Phone:   |   |   | Height:  | _ Weight:                       | lbs  | kg        |
| Address:  |   |   |  | _ Email:                        |  |           |
| Allergies:  |   |   |  |                                 | NKDA   |           |
| Patient status:   | ☐ New to therapy  | ☐ Continuing therapy                            | Last Treatment Date:   | N                               | Vext Treatment Date:                         |           |
| Alzheimer's Dise  | ease G30.1<br>npairment G31.84                                      |   | ☐ Alzheimer's Disease G30☐ Other Alzheimer's Disea   |                                 |  |           |
| REGISTRY NU Registry Number:  | MBER - (requir  | ed for patients with                            | h Medicare)  |                                 |  |           |
| PROVIDER  |   |   |  |                                 |  |           |
|   |   |   | Provider NPI:  |                                 |  |           |
|   |   |   | Referral Coordinator Name  |                                 |  |           |
|   |   |   |  |                                 |  |           |
| Phone:  | Fax   | :   | Email:   |                                 |  |           |
| PRE-MEDICAT  Acetaminophen  Diphenhydramin  Methylprednisol  Cetrizine (Zyrted)  Other: | (Tylenol) PO<br>ne (Benadryl) Plone (Solu-Medrol) IV<br>c) 10 mg PO | ☐ 500 mg<br>0 ☐ IV ☐ 25 mg<br>☐ 40 mg           |  | ☐ 650 mg<br>☐ 50 mg<br>☐ 125 mg |  |           |
| THERAPY ADI   | MINISTRATION  |   |  |                                 |  |           |
|   | 12 months<br>ninutes.<br>sodium chloride at in                      | followed by 1400 Order valid fusion completion. | or four weeks for the first three<br>O mg every four weeks.<br>I for 1 year unless otherwise s | e doses,                        | requency  ☑ Every 4 weeks  dure observation. |           |
| •   | •   | aining an MRI prior to the 2                    | 2nd, 3rd, 4th, and 7th infusion  | ns                              |  |           |
| LABORATORY  CBC CMP CRP Other   | ORDERS  | at each dose at each dose at each dose          | every<br>every<br>every  |                                 |  |           |
| SPECIAL INSTR   | EUCTIONS  |   |  |                                 |  |           |
| Provider Signat   | ture  |   | Date   |                                 |  |           |
| UPTIVHEALTH.C   | OM Pho  | ne: (734) 203-0176                              | Fax: (888) 373-5528  | Email                           | referral@untivhe                             | ealth.com |